scholarly journals A Quantitative Chemotherapy Genetic Interaction Map Reveals Factors Associated with PARP Inhibitor Resistance

Cell Reports ◽  
2018 ◽  
Vol 23 (3) ◽  
pp. 918-929 ◽  
Author(s):  
Hsien-Ming Hu ◽  
Xin Zhao ◽  
Swati Kaushik ◽  
Lilliane Robillard ◽  
Antoine Barthelet ◽  
...  
Keyword(s):  
Genetic Interaction ◽  
Parp Inhibitor ◽  
Factors Associated ◽  
Interaction Map ◽  
Inhibitor Resistance

scholarly journals A quantitative chemotherapy genetic interaction map reveals new factors associated with PARP inhibitor resistance

2017 ◽  
Author(s):  
Hsien-Ming Hu ◽  
Xin Zhao ◽  
Swati Kaushik ◽  
Lilliane Robillard ◽  
Antoine Barthelet ◽  
...  
Keyword(s):  
Dna Repair ◽  
Cancer Cell ◽  
Mammary Epithelial Cells ◽  
Genetic Interaction ◽  
Parp Inhibitor ◽  
Cancer Cell Line ◽  
Parp Inhibitors ◽  
Mammary Epithelial ◽  
Interaction Map ◽  
The Impact

SUMMARYNearly every cancer patient is treated with chemotherapy yet our understanding of factors that dictate response and resistance to such agents remains limited. We report the generation of a quantitative chemical-genetic interaction map in human mammary epithelial cells that charts the impact of knockdown of 625 cancer and DNA repair related genes on sensitivity to 29 drugs, covering all classes of cancer chemotherapeutics. This quantitative map is predictive of interactions maintained in cancer cell lines and can be used to identify new cancer-associated DNA repair factors, predict cancer cell line responses to therapy and prioritize drug combinations. We identify that GPBP1 loss in breast and ovarian cancer confers resistance to cisplatin and PARP inhibitors through the regulation of genes involved in homologous recombination. This map may help navigate patient genomic data and optimize chemotherapeutic regimens by delineating factors involved in the response to specific types of DNA damage.

scholarly journals 53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells

BMC Cancer ◽  
2016 ◽  
Vol 16 (1) ◽  
Author(s):  
Ruoxi Hong ◽  
Fei Ma ◽  
Weimin Zhang ◽  
Xiying Yu ◽  
Qing Li ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Parp Inhibitor ◽  
Inhibitor Resistance

Tackling PARP inhibitor resistance

2021 ◽  
Author(s):  
Kasper Fugger ◽  
Graeme Hewitt ◽  
Stephen C. West ◽  
Simon J. Boulton
Keyword(s):  
Parp Inhibitor ◽  
Inhibitor Resistance

scholarly journals PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies

Cancers ◽  
2020 ◽  
Vol 12 (8) ◽  
pp. 2054
Author(s):  
Elizabeth K. Lee ◽  
Ursula A. Matulonis
Keyword(s):  
Synthetic Lethality ◽  
Parp Inhibitor ◽  
Parp Inhibitors ◽  
Resistance Mechanisms ◽  
Parp Inhibition ◽  
Combination Therapies ◽  
Mechanisms Of Resistance ◽  
Damage Repair ◽  
Inhibitor Resistance

The use of PARP inhibitors (PARPi) is growing widely as FDA approvals have shifted its use from the recurrence setting to the frontline setting. In parallel, the population developing PARPi resistance is increasing. Here we review the role of PARP, DNA damage repair, and synthetic lethality. We discuss mechanisms of resistance to PARP inhibition and how this informs on novel combinations to re-sensitize cancer cells to PARPi.

scholarly journals PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells

2019 ◽  
Vol 29 (10) ◽  
pp. 820-834 ◽  
Author(s):  
Sylvie M. Noordermeer ◽  
Haico van Attikum
Keyword(s):  
Parp Inhibitor ◽  
Inhibitor Resistance

scholarly journals Amplification of the Mutation-Carrying BRCA2 Allele Promotes RAD51 Loading and PARP Inhibitor Resistance in the Absence of Reversion Mutations

2019 ◽  
Vol 19 (2) ◽  
pp. 602-613 ◽  
Author(s):  
Pyoung Hwa Park ◽  
Tomomi M. Yamamoto ◽  
Hua Li ◽  
Allen L. Alcivar ◽  
Bing Xia ◽  
...  
Keyword(s):  
Parp Inhibitor ◽  
Inhibitor Resistance
Sign in / Sign up

Export Citation Format

Share Document